Racotumomab is under clinical development by Recombio and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Racotumomab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Racotumomab overview

Racotumomab (1E10 Mab, anti-idiotype cancer vaccine, Vaxira) is under development for the treatment of neuroblastoma. The drug candidate is administered through the intradermal route. Racotumomab is a murine monoclonal antibody designed to elicit a specific immune response against glycolylated gangliosides (NeuGcGM3) present in the tumor cells. It was also under development for breast cancer, small-cell lung cancer, melanoma, non-small cell lung cancer (NSCLC), Ewing sarcoma, glioma, retinoblastoma and Wilms' tumor (nephroblastoma).

Recombio overview

Recombio is developer and manufacturer of innovative products, focusing on immunotherapy of chronic diseases. The company carries out investigation, development and manufacture of products which concentrates on immunotherapy for viral diseases and cancer. Its products comprise mono-sialyl lactose ceramides, Recombios anti-cancer vaccines and others. Recombio develops research projects with anti-cancer vaccines by manufacturing monoclonal antibodies and vaccine nanovesicles related to mono-sialyl lactose ceramides. The company carries out ambitious program of clinical trials in the fields of cancer and HIV and AIDS. It operates centers in Argentina and Cuba. Recombio is headquartered in Madrid, Spain.

For a complete picture of Racotumomab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.